
åºç€çŸæ£ã®ãªã26æ³å¥³æ§ãã³ããã¯ã¯ãã³æ¥çš®4æ¥åŸã«æ»äº¡ããäºäŸãèªå®
12æ12æ¥ã«éå¬ãããã第154åãææçã»äºé²æ¥çš®å¯©æ»åç§äŒãã§ãã³ããã¯ã¯ãã³æ¥çš®åŸã®æ»äº¡ãªã©ãæ°ãã«14ä»¶ãèªå®ãããŸããã
ããèäžåºè¡ãè³æ¢å¡ãªã©ãèªå®
äºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠã«ã€ããŠã¯ãäžèšã®èšäºã§è©³ããåãäžããŸããã
ãå³å¯ãªå»åŠçãªå æé¢ä¿ãŸã§ã¯å¿ èŠãšãããæ¥çš®åŸã®çç¶ãäºé²æ¥çš®ã«ãã£ãŠèµ·ããããšãåŠå®ã§ããªãå Žåã察象ãšããããšããæ¹éã§å¯©æ»ãè¡ãããŠããŸãããã©ã®ãããªå¯©æ»åºæºãªã®ããäžéæã§ãã
ãããŸã§ã®å¯©æ»çµæã¯ãååŽçã®ãµã€ãã§å ¬éãããŠããŸãã
12æ12æ¥ã®å¯©æ»çµæ

åºç€çŸæ£ãªãã®26æ³å¥³æ§ãã³ããã¯ã¯ãã³æ¥çš®åŸã«ãããèäžåºè¡ã§äº¡ããªã£ãäºäŸãèªå®ãããŸããããã®æ å ±ã ãã§ã¯è©³ããããšã¯ããããŸããããããããã2021幎3æã«äº¡ããªã£ãå»çåŸäºè ã®æ¹ã ãšæããŸãããã®äºäŸã¯ãšãŠãè¡æçã ã£ãã®ã§èŠããŠããæ¹ãå€ããTwitterã§ã26æ³å¥³æ§ã¯ãã®äºäŸã§ã¯ãªãããšãã声ã倿°èŠãããŸããã
ãã®äºäŸãšãèªå®ããã26æ³å¥³æ§ãåäžäººç©ãã¯ç¢ºå®ããŠããŸããããéåžžã«éèŠãªäºäŸãªã®ã§å床åãäžããŸãã
æ¥çš®åŸã®æ»äº¡äºäŸïŒãšããŠã2021幎5æ12æ¥ã«ååŽçã®ãµã€ãã§å ±åãå ¬éãããŸãããäžèšã®èšäºã§ãåãäžããŠããŸãã
æåã®é ã¯ãæ»äº¡äºäŸã«ã€ããŠã¯ãã¹ãŠè©³çްãå
¬éãããŠããŸããã
(1) æ£è èæ¯ã26 æ³ã®å¥³æ§
(2) æ¥çš®ãããã¯ã¯ãã³ã«ã€ããŠ
ãã¡ã€ã¶ãŒæ ªåŒäŒç€Ÿãã³ãããã£ç泚ã ãããçªå·ïŒEP9605
æ¥çš®åæ°ïŒåç®
(3) åºç€çŸæ£çãç¡
(4) çç¶ã®æŠèŠ
æ¥ç𮿥æïŒä»€åïŒå¹ŽïŒæ 19 æ¥ååŸ 14 æ
çºçæ¥æïŒä»€åïŒå¹ŽïŒæ 23 æ¥åå 11 æé
æ» å çïŒè³åºè¡ïŒå°è³ïŒãããèäžåºè¡
æŠ èŠïŒïŒæ 19 æ¥ã¯ã¯ãã³æ¥çš®ïŒïŒåç®ïŒãæ¥çš®åŸãã¢ããã£ã©ãã·ãŒçãªããäœèª¿å€åãªãã
ïŒæ 22 æ¥ éåžžå€åã
ïŒæ 23 æ¥ å€å€ã ãåºå€ããããå®¶æãžé£çµ¡ããåœé¢è·å¡ãèªå® ãžãå®¶æãèŠå¯ãææ¥éãå ã«ååŸïŒæ 15 åé å°ç
ããæ»äº¡ç¢ºèªããããæ€æ»ã«ããåå 11 æé ã®æ»äº¡ãšæšå®ããããAI ã®ããåœé¢ãžååŸïŒæ 48 åå°çãå šèº« CT ã®çµæãé éš CTãå°è³å·Šåç CP Angle ã«ãããçŽåŸ 3.5cm ã®è¡è «ãããç³ç°åïŒïŒïŒã§åœ¢æ ããè¡ç®¡è «ãé«èè «ãªã©ã®è¡ç®¡æ§è «çããã®åºè¡ãçããããè³åèç€ã®å¯èœæ§ããããè³å¹¹ãžã®å§æãå·ŠèåŽãããããåšå²ã«ããèäžåºè¡ã®ã²ããããããåŽè³å®€å ã«è¡æ¶²æµå ¥ãããèºéã§ã¯äž¡åŽèºã«äžæ¢åŽãäžå¿ã«èºæ°Žè «ã®æèŠããããã£ãŠãå°è³åºè¡ã®è³å¹¹éšå§æãããèäžåºè¡çãè³åºè¡ãçŽæ¥æ»å ãšããã
æ£è ã®å®¶æã®æåããã忀ã¯å®æœãããªãã£ãããšã確èªãããã
æ¬å€ã¯ãïŒæ 19 æ¥ååŸ 14 æçèå æäžãããã
æ¬ã¯ã¯ãã³ååæ¥çš®æ¥åïŒé±é以å ã®ã¯ã¯ãã³æ¥çš®æŽã¯ãªãã£ãã
äºè±¡ã®çºçŸåïŒé±é以å ã®äœµçšè¬æäžã¯ãªãã£ãã
é¢é£ããç æŽã¯ãªãã£ããå®¶ææŽã«ã¯é«è¡å§ãšç³å°¿ç ããã£ãã
SARS-CoV-2 æäœå®æ§è©ŠéšïŒé°æ§ãSARS-CoV-2 æäœå®é詊éšïŒé°æ§ãSARS-CoV-2 PCR æ€æ»ïŒé°æ§ïŒãããã什åïŒå¹ŽïŒæ 23 æ¥ïŒã
é éš MRI ãšåæ€ã¯æœè¡ãããªãã£ããããè³åéèå¥åœ¢(AVM)ã®å¯èœæ§ã®æç¡ã¯å€æã§ããªãã£ãã
(5) ã¯ã¯ãã³æ¥çš®ãšã®å æé¢ä¿ïŒå ±åè ã®è©äŸ¡ïŒ
è©äŸ¡äžèœ
å ±åè æèŠïŒAI ç»åã§ã¯ãäžèšæèŠãèªãçŽæ¥æ»å ãšå€æãããã¯ã¯ãã³æ¥çš®ãšæ»äº¡ã®å æé¢ä¿ã¯ãè©äŸ¡äžèœã ã£ãã
ä»èŠå ã®å¯èœæ§ã®æç¡ïŒæïŒè³åºè¡ïŒå°è³ïŒãããèäžåºè¡ïŒ
(6) å°éå®¶ã®è©äŸ¡
âå æé¢ä¿è©äŸ¡ïŒÎ³
âå°éå®¶ã³ã¡ã³ãïŒæ»äº¡æç»å蚺æïŒCTïŒã«ãŠãå°è³åçããå°è³æ©è§éšã«ãããŠç³ç°åã䌎ãè¡è «ãèªããŠãããè³åéèå¥åœ¢ãæµ·ç¶¿ç¶è¡ç®¡è «ã®ååšã瀺åãããããç¹å®ã®ããã«ã¯åæ€ãªã©ã®ããè©³çŽ°ãªæ å ±ãå¿ èŠã§ãããè³åºè¡ã«ããæ»äº¡ãšã¯ã¯ãã³æ¥çš®ã®å æé¢ä¿ã¯è©äŸ¡äžèœã§ããã
泚ïŒ3 æ 26 æ¥ã®ååéšäŒè³æã§ã¯ããè³åéèå¥åœ¢ãããè³åéèç€ããšèª€èšèŒã
ãå€å€ã ãåºå€ããããå®¶æãžé£çµ¡ããåœé¢è·å¡ãèªå® ãžããšæžãããŠãããé«éœ¢è ãžã®åªå æ¥çš®ãéå§ããã®ãïŒæ12æ¥ãªã®ã§ããã®å¥³æ§ã¯å»çåŸäºè ã§ãããã
é±åèªçã§ã¯ã圌女ã¯çè·åž«ã§ãæ¬äººã¯æ¥çš®ããããªãã£ãããã©ãå€åããŠããç æ£ã®é¢ä¿ã§æ¥çš®ããããåŸãªãã£ããšæžãããŠããŸããã
2021幎5æã®æç¹ã§ã¯å æé¢ä¿ã¯ãè©äŸ¡äžèœããšãªã£ãŠããã®ã§ãææ°ã®æ å ±ã確èªããŠã¿ãŸããã
No.2ã
å°éå®¶ã«ããè©äŸ¡ã什å4幎11æ11æ¥æç¹ã
忀ãªã©ã®ç²Ÿæ»ã¯å®æœãããŠããããåºè¡æºã®ç¢ºå®ã«ã¯è³ã£ãŠããªããã®ã®ãæ»äº¡æç»å蚺æïŒCTïŒã«ãŠãå°è³åçããå°è³æ©è§éšã«ãããŠç³ç°åã䌎ãè¡è «ãèªããŠãããåºè¡ãªã¹ã¯ãé«ãç å€ãååšããŠããå¯èœæ§ã瀺åããããã¯ã¯ãã³æ¥çš®ãè³åºè¡ã®çºçãæ»äº¡ã«ã©ã®ãããª
圱é¿ãäžãããã¯äžæã§ããã
â»ïœ10/7ãã倿Žãªãã
ãã¯ããγïŒè©äŸ¡äžèœïŒã®ãŸãŸã§ãã
å¯åå¿çãã®å ±åã§ã¯ããã¡ã€ã¶ãŒè£œã³ããã¯ã¯ãã³æ¥çš®åŸã«æ»äº¡ããæ¹ã§ãαãšè©äŸ¡ãããäºäŸã¯ãŸã ãããŸããã

ããã©ããäºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠã§ã¯ã15äººã®æ»äº¡ãèªå®ãããŸããã
ææžå¶åºŠã§èªå®ããããšããããšã¯ãå°ãªããšããæ¥çš®åŸã®çç¶ãã³ããã¯ã¯ãã³æ¥çš®ã«ãã£ãŠèµ·ããããšãåŠå®ã§ããªãããšããããšã§ãã
ããèäžåºè¡ãè³æ¢å¡ã¯ã以åã®èšäºïŒäžèšåç §ïŒã§ç޹ä»ãããå°å³¶å¢äºæ°ïŒåå€å±å€§åŠåèªææã»åå€å±å°å ããåºéçäºé·ïŒã解説ããŠããæ»å ãšéãªããŸãã

å»çåŸäºè
ã®æ¥çš®ãå§ãŸã£ãŠãããã£ãšå¯åå¿çãã®å ±åããã§ãã¯ããŠããŸããããã®äºäŸãèŠããšãããšãŠãæãããããšãèµ·ããŠãããšæããŸãããåºç€çŸæ£ããªããå»çåŸäºè
ãšããŠæ®éã«åããŠãã26æ³ã®å¥³æ§ããã¯ã¯ãã³æ¥çš®4æ¥åŸã«æ¥æ»ãããªããŠã
ããã©ãããã®äºäŸã¯ãã¬ãã§å€§ããå ±ããããããšã¯ãªãã£ããšèšæ¶ããŠããŸããããã©ãããããã®äºäŸã¯ããæ±ããŸã§ãããŸãããäŸãã°ãäžèšã®èšäºã§æå»åž«ã¯ãã®äºäŸã«ã€ããŠãã¯ã¯ãã³ãæã£ãããšã«ããŸããŸè³åºè¡ãèµ·ãããå¯èœæ§ãé«ããå æé¢ä¿ã®èª€è§£éã§ãããããšèšã£ãŠããŸããã以äžããã®éšåãåŒçšããŸãã
ïŒå1ïŒ
ãã¡ã€ã¶ãŒã®ã¯ã¯ãã³ã¯è³åºè¡ãèµ·ããããããæ»äº¡è ãåºã
ãæ¥æ¬ã§ã¯ã¯ãã³æ¥çš®åŸã4æ¥åŸã«åºç€çŸæ£ã®ãªã26æ³ã®å¥³æ§ãè³åºè¡ã§äº¡ããªã£ãããšãå ±åããããã¢ã¡ãªã«ã§ãåæ§ã®è³åºè¡ã®å ±åã¯ãã£ããšãããâŠâŠã
ãã¢ã¡ãªã«ã§ã¯2åå以äžããã¡ã€ã¶ãŒã®mRNAã¯ã¯ãã³ãæãããŠããŸãããè³åºè¡ãå¢ãããšããå ±åã¯äžåãããŸããã
ããšãæšäžå çã
ãã¯ã¯ãã³ãæã£ãããšã«ããŸããŸè³åºè¡ãèµ·ãããå¯èœæ§ãé«ããå æé¢ä¿ã®èª€è§£éã§ããããïŒæšäžå çã以äžåïŒ
ãã ããæ»äº¡è ãåºããšèãã°äžå®ã«ãªãã®ãåœããåã
ãã¯ã¯ãã³ãæã£ãããšã«èµ·ããããã¹ãŠã®äœèª¿äžè¯ããæå®³äºè±¡ããšãããŸããäŸãã°ãã¯ã¯ãã³ãæã£ãããšã«äº€éäºæ ã«éã£ãããšããæå®³äºè±¡ãã§ããããã¯ã¯ã¯ãã³ãåå ã§ãªãããšã¯æããã§ããè³åºè¡ã®ã±ãŒã¹ããããã£ããæå®³äºè±¡ãã®ã²ãšã€ã§ããããäžæ¹ãã¯ã¯ãã³ãåå ãšèãããããã®ããå¯åå¿ããšãããŸãã
ãäœããèµ·ãããšãããæå®³äºè±¡ãããå¯åå¿ããªã®ããèŠæ¥µããããšã倧åã ãšããã
ãã¢ã¡ãªã«ã«ã¯ãæå®³äºè±¡å ±åã·ã¹ãã ããšããã®ããããäœèª¿äžè¯ãªã©ãèªç¶çºçä»¶æ°ããå€ããã©ããã調ã¹ããã§ãã¯ããŠãããŸããããã¯å»åž«ã ãã§ãªããæ£è ãå ±åã§ããèšå€§ãªå ±åãåºã«ã¯ã¯ãã³ãšäœèª¿äžè¯ã®å æé¢ä¿ãè§£æããŠãããŸãããã®çµæãä»ã®ãšããè³åºè¡ã¯ãå¯åå¿ãã§ã¯ãªããšãããŸãã
ãã®äºäŸãããã¯ã¯ãã³ãæã£ãããšã«äº€éäºæ
ã«éã£ãããšããšååã«æ±ã£ãŠããŸãããªããã®æç¹ã§ãå æé¢ä¿ã®èª€è§£éãªã©ãšæèšã§ããã®ã§ããããã
ãã¬ãã«åºãŠãããããªå»åž«ãå°éå®¶ãšåŒã°ãã人ãã¡ã¯ãæ¥çš®ãå§ããã°ããã§ããã®ãããªäºäŸãèŠèŽè
ã«ç¥ãããããšã¯ãããŸããã§ããã
ãããŠ1幎以äžçµã£ãŠãå°ããã€æ»äº¡äºäŸãææžå¶åºŠã§èªå®ãããŠããŸããããã§ãåœã¯ãã¯ã¯ãã³æ¥çš®ãæ¢ããæ°ã¯ãããŸãããåœãå§ããŠãããããšãã£ãŠãå®å šãšããããã§ã¯ãªãã®ã§ããéå»ã®è¬å®³äºä»¶ã§ããåããããªããšããããŸããã
ãåªå矩åãã¯ã矩åã§ã¯ãããŸãããæ¥çš®ãããããªããã¯ãèªåã§æ±ºããŠããã¯ãã§ããè·å Žã®å§åãªã©ã§ãæ¥çš®åŸã«äº¡ããªã£ã26æ³å¥³æ§ã®ãããªæ¹ããã以äžå¢ãããŠã¯ãããªããšæããŸãã